Gene therapy rising: Bluebird soars at ASH, Pfizer builds platform
This article was originally published in Scrip
With the potential to cure debilitating diseases, gene therapy has become a darling of the biotechnology industry. The latest evidence: Bluebird Bio's 8 December after-hours stock market rise by 43.2% to $70 per share on data from four transfusion-free beta-thalassemia patients and Pfizer's investment in a gene therapy platform that includes a hemophilia B collaboration with Spark Therapeutics.
You may also be interested in...
As updated Phase I/II results for BioMarin's hemophilia A and Spark's hemophilia B gene therapies were presented on May 22, it was revealed that FDA plans to make hemophilia the first gene therapy indication eligible for accelerated approval based on a surrogate endpoint.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.